SWOG clinical trial number
CTSU/A091605

A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma

Open
Abbreviated Title
A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma
Status Notes
SWOG Activated: 8/26/2019
Activated
02/01/2018

Research committees

Early Therapeutics & Rare Cancers
Melanoma

Publication Information Expand/Collapse

2018

A Randomized Phase II Study of Anti-Pd1 Antibody [Mk-3475 (Pembrolizumab)] Alone Versus Anti-Pd1 Antibody plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma

J Luke;S Chmura;J Salama;H Al-Hallaq;C Hsu;S Yom;M Kozloff;J Allred;P Munster;G Schwartz J Clin Oncol 36, 2018 (suppl; abstr TPS9599); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), poster

Other Clinical Trials

SWOG Clinical Trial Number
CTSU/EA6174

A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Research Committee(s)
Melanoma
Activated
10/01/2018
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6141

Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Research Committee(s)
Melanoma
Activated
09/10/2015
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6134

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma
Research Committee(s)
Melanoma
Activated
07/13/2015
Open
Phase